{
    "symbol": "INMB",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 18:35:23",
    "content": " And the company's preclinical data with human NK cells targeting cancer cells shows that INKmune primes the NK cells from patients and from healthy donors to lies NK-resistant solid tumors from ovarian cancer, breast cancer, prostate cancer, renal cell carcinoma and most recently, nasopharyngeal cancer cells. Our chief investigator, who looks after the trial and has treated all 4 patients, said recently, \u00e2\u0080\u009call enjoyed improvement in general fitness with resolution of fevers, stabilized or even improved blood counts and were able to give brakes from the low-dose chemotherapy they've been receiving.\u00e2\u0080\u009d Definite improvement in subjective parameters of well-being mood, appetite and indeed clinical performance status. Although our Phase II Expo trial for treatment of neuroinflammation as it cause Alzheimer's disease is currently on hold pending the FDA manufacturing review, we expect to continue enrolling patients over the coming months with attention to Australia in order to reach the enrollment target of 201."
}